Weekly Recap: EPCORE DLBCL-2 positive results and DARZALEX Q3 2026 sales
Genmab reported that epcoritamab plus R-CHOP reduced the risk of progression or death by 51% compared to R-CHOP alone in the Phase 3 EPCORE DLBCL-2 trial. The company plans to present these results and share them with regulators. Additionally, Genmab announced Q3 2026 net sales of $4.239B for DARZALEX, generating royalties for the company.
How this was made
The 30-second read
Why it matters
The 51% risk reduction is a strong efficacy signal that could accelerate regulatory submissions and increase royalty income from Darzalex sales.
Market read
Positive Phase 3 data is a catalyst for Genmab's stock and may influence peer valuations in the lymphoma therapeutic space.
What to watch
Potential competition from other CD20‑targeted therapies and the need for FDA filing timelines.
Background
Genmab is a Copenhagen‑based biotech with a U.S. ADR (GMAB). The EPCORE DLBCL‑2 trial evaluates epcoritamab, a bispecific antibody, in combination with standard R‑CHOP chemotherapy for newly diagnosed diffuse large B‑cell lymphoma.
Ticker impact
Genmab reported Phase 3 EPCORE DLBCL-2 trial data showing epcoritamab plus R-CHOP cut progression or death risk by 51% versus R-CHOP alone.
likely upward pressure as investors price in the efficacy boost
Phase 3 results are material for a biotech; a 51% risk reduction is a strong efficacy signal that typically lifts share price.
Market effects
May lift other lymphoma‑focused biotech stocks as investors reassess the market potential of epcoritamab.
European biotech sector could see modest gains on the news.
Limited to biotech investors; no broad market effect.
Counterpoint
If regulatory review raises concerns about safety or commercial viability, the rally could be muted.
Key entities
- CompanyGenmab A/S
Biotech developer of epcoritamab and royalty holder for Darzalex.
